Memphasys Ltd (MEM) - Total Assets
Based on the latest financial reports, Memphasys Ltd (MEM) holds total assets worth AU$10.45 Million AUD (≈ $7.39 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Memphasys Ltd net assets for net asset value and shareholders' equity analysis.
Memphasys Ltd - Total Assets Trend (2007–2025)
This chart illustrates how Memphasys Ltd's total assets have evolved over time, based on quarterly financial data.
Memphasys Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Memphasys Ltd's total assets of AU$10.45 Million consist of 12.1% current assets and 87.9% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 2.7% |
| Accounts Receivable | AU$900.94K | 8.2% |
| Inventory | AU$58.82K | 0.5% |
| Property, Plant & Equipment | AU$567.43K | 5.2% |
| Intangible Assets | AU$9.11 Million | 82.6% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2007–2025)
This chart illustrates how Memphasys Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see MEM market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Memphasys Ltd's current assets represent 12.1% of total assets in 2025, an increase from 0.0% in 2007.
- Cash Position: Cash and equivalents constituted 2.7% of total assets in 2025, down from 4.7% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 82.0% of total assets, an increase from 0.0% in 2007.
- Asset Diversification: The largest asset category is intangible assets at 82.6% of total assets.
Memphasys Ltd Competitors by Total Assets
Key competitors of Memphasys Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Vitrolife AB
ST:VITR
|
Sweden | Skr11.12 Billion |
|
Medprin Regenerative Medical Technologies Co. Ltd.
SHE:301033
|
China | CN¥805.10 Million |
|
Tellgen Corp
SHE:300642
|
China | CN¥2.00 Billion |
|
Lumos Diagnostics Holdings Ltd
AU:LDX
|
Australia | AU$20.81 Million |
|
T&R Biofab Co. Ltd
KQ:246710
|
Korea | ₩83.86 Billion |
|
Ok Biotech Co Ltd
TW:4155
|
Taiwan | NT$3.89 Billion |
|
Promimic AB
ST:PRO
|
Sweden | Skr75.71 Million |
|
Iconovo
ST:ICO
|
Sweden | Skr131.08 Million |
Memphasys Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.14 | 0.26 | 2.64 |
| Quick Ratio | 0.10 | 0.22 | 2.51 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$-5.30 Million | AU$-3.39 Million | AU$1.31 Million |
Memphasys Ltd - Advanced Valuation Insights
This section examines the relationship between Memphasys Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.25 |
| Latest Market Cap to Assets Ratio | 0.91 |
| Asset Growth Rate (YoY) | -11.3% |
| Total Assets | AU$11.02 Million |
| Market Capitalization | $10.07 Million USD |
Valuation Analysis
Near Book Valuation: The market values Memphasys Ltd's assets close to their book value (0.91x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Memphasys Ltd's assets decreased by 11.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Memphasys Ltd (2007–2025)
The table below shows the annual total assets of Memphasys Ltd from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$11.02 Million ≈ $7.80 Million |
-11.33% |
| 2024-06-30 | AU$12.43 Million ≈ $8.80 Million |
-15.26% |
| 2023-06-30 | AU$14.67 Million ≈ $10.38 Million |
+3.87% |
| 2022-06-30 | AU$14.12 Million ≈ $9.99 Million |
-3.15% |
| 2021-06-30 | AU$14.58 Million ≈ $10.32 Million |
+29.05% |
| 2020-06-30 | AU$11.30 Million ≈ $7.99 Million |
+65.27% |
| 2019-06-30 | AU$6.84 Million ≈ $4.84 Million |
+62.11% |
| 2018-06-30 | AU$4.22 Million ≈ $2.98 Million |
-42.24% |
| 2017-06-30 | AU$7.30 Million ≈ $5.17 Million |
+1.49% |
| 2016-06-30 | AU$7.19 Million ≈ $5.09 Million |
+5.11% |
| 2015-06-30 | AU$6.84 Million ≈ $4.84 Million |
-3.63% |
| 2014-06-30 | AU$7.10 Million ≈ $5.03 Million |
-47.90% |
| 2013-06-30 | AU$13.63 Million ≈ $9.65 Million |
+52.28% |
| 2012-06-30 | AU$8.95 Million ≈ $6.33 Million |
-15.32% |
| 2011-06-30 | AU$10.57 Million ≈ $7.48 Million |
-40.33% |
| 2010-06-30 | AU$17.72 Million ≈ $12.54 Million |
+207.77% |
| 2009-06-30 | AU$5.76 Million ≈ $4.07 Million |
+13.86% |
| 2008-06-30 | AU$5.06 Million ≈ $3.58 Million |
+13.28% |
| 2007-06-30 | AU$4.46 Million ≈ $3.16 Million |
-- |
About Memphasys Ltd
Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company offers Felix system, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, a rapid in vitro antioxidant assessment; and AI-Port… Read more